X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Wockhardt - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs WOCKHARDT LTD. - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA WOCKHARDT LTD. AUROBINDO PHARMA/
WOCKHARDT LTD.
 
P/E (TTM) x 16.0 -18.6 - View Chart
P/BV x 4.1 3.1 134.3% View Chart
Dividend Yield % 0.4 1.1 35.3%  

Financials

 AUROBINDO PHARMA   WOCKHARDT LTD.
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
WOCKHARDT LTD.
Mar-17
AUROBINDO PHARMA/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs8951,129 79.3%   
Low Rs622627 99.2%   
Sales per share (Unadj.) Rs254.6363.1 70.1%  
Earnings per share (Unadj.) Rs39.3-20.4 -192.1%  
Cash flow per share (Unadj.) Rs46.6-7.0 -667.8%  
Dividends per share (Unadj.) Rs2.5010.00 25.0%  
Dividend yield (eoy) %0.31.1 28.9%  
Book value per share (Unadj.) Rs160.0301.8 53.0%  
Shares outstanding (eoy) m585.88110.55 530.0%   
Bonus/Rights/Conversions ESOPIS-  
Price / Sales ratio x3.02.4 123.2%   
Avg P/E ratio x19.3-42.9 -45.0%  
P/CF ratio (eoy) x16.3-125.9 -12.9%  
Price / Book Value ratio x4.72.9 163.0%  
Dividend payout %6.4-48.9 -13.0%   
Avg Mkt Cap Rs m444,39097,063 457.8%   
No. of employees `00014.06.8 206.6%   
Total wages/salary Rs m17,6789,665 182.9%   
Avg. sales/employee Rs Th10,667.85,931.8 179.8%   
Avg. wages/employee Rs Th1,264.31,428.1 88.5%   
Avg. net profit/employee Rs Th1,645.8-334.0 -492.8%   
INCOME DATA
Net Sales Rs m149,15740,146 371.5%  
Other income Rs m1,1591,143 101.4%   
Total revenues Rs m150,31641,289 364.1%   
Gross profit Rs m34,343128 26,830.3%  
Depreciation Rs m4,2761,489 287.1%   
Interest Rs m6672,253 29.6%   
Profit before tax Rs m30,558-2,472 -1,236.4%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597-211 -3,598.5%   
Profit after tax Rs m23,012-2,260 -1,018.0%  
Gross profit margin %23.00.3 7,221.5%  
Effective tax rate %24.98.5 291.0%   
Net profit margin %15.4-5.6 -274.0%  
BALANCE SHEET DATA
Current assets Rs m92,06246,160 199.4%   
Current liabilities Rs m66,22319,258 343.9%   
Net working cap to sales %17.367.0 25.9%  
Current ratio x1.42.4 58.0%  
Inventory Days Days106101 105.2%  
Debtors Days Days6894 72.0%  
Net fixed assets Rs m62,91940,165 156.7%   
Share capital Rs m586553 106.0%   
"Free" reserves Rs m93,13332,814 283.8%   
Net worth Rs m93,71933,367 280.9%   
Long term debt Rs m1,81431,903 5.7%   
Total assets Rs m162,49489,687 181.2%  
Interest coverage x46.8-0.1 -48,184.6%   
Debt to equity ratio x01.0 2.0%  
Sales to assets ratio x0.90.4 205.1%   
Return on assets %14.60 -169,732.7%  
Return on equity %24.6-6.8 -362.5%  
Return on capital %32.7-0.3 -9,766.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,8389,121 831.5%   
Fx outflow Rs m30,2242,133 1,416.9%   
Net fx Rs m45,6136,988 652.8%   
CASH FLOW
From Operations Rs m32,786-2,695 -1,216.7%  
From Investments Rs m-17,870-6,863 260.4%  
From Financial Activity Rs m-19,15312,545 -152.7%  
Net Cashflow Rs m-4,2393,010 -140.8%  

Share Holding

Indian Promoters % 54.1 74.5 72.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.3 345.7%  
FIIs % 27.7 7.7 359.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 10.2 15.4 66.2%  
Shareholders   69,601 67,757 102.7%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Airtel, Idea Down by 5%(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

'Smart Money' Enters Bitcoin. Will You?(Smart Contrarian)

Jan 17, 2018

As institutional money enters bitcoin, the gains over the last year could just be the tip of the iceberg.

Increasing Divergence Between Bond Yields and Earnings Yield(Chart Of The Day)

Jan 11, 2018

Over the past couple of months, bond yields have risen, but earning yields have fallen, increasing divergence.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jan 24, 2018 02:45 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS